Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker has maintained a Buy rating on Eton Pharmaceuticals and raised the price target from $10 to $15.
October 28, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Craig-Hallum has increased the price target for Eton Pharmaceuticals from $10 to $15, maintaining a Buy rating. This suggests a positive outlook for the company's stock.
The increase in price target from $10 to $15 by Craig-Hallum indicates a strong positive sentiment towards Eton Pharmaceuticals. Maintaining a Buy rating suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100